Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will
commercialise NaMuscla for the symptomatic treatment of myotonia in
adults with non-dystrophic myotonic (NDM) disorders in certain
European Union (EU) territories, Lupin said in a statement.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-inks-distribution-pact-with-3-firms-to-commercialise-namuscla-in-europe/articleshow/76171829.cms
No comments:
Post a Comment